Imaging Pancreatic Cancer with a Peptide−Nanoparticle Conjugate Targeted to Normal Pancreas
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Designing molecules that bind to targets that become upregulated or overexpressed as normal cells become cancerous is an important strategy for both therapeutic and diagnostic drug design. We hypothesized that pancreatic ductal adenocarcinoma (PDAC) might be imaged with the inverse strategy, that is by the design of a nanoparticle-conjugate targeted to bombesin (BN) receptors present on normal acinar cells of the pancreas. Using the fluorescein hapten visualization method to assess the presence of bombesin (BN) receptors, we first demonstrated BN receptors in the normal mouse and human pancreas, but then the lack of BN binding receptors in 13 out of 13 specimens of PDAC. The BN peptide-nanoparticle conjugate, BN-CLIO(Cy5.5), was synthesized and accumulated in the mouse pancreas in receptor dependent fashion, but not in a receptor dependent fashion in other tissues, based on tissue fluorescence measurements. The BN-CLIO(Cy5.5) nanoparticle decreased the T2 of normal pancreas and enhanced the ability to visualize tumor in a model of pancreatic cancer by MRI. The use of BN-CLIO(Cy5.5) nanoparticle as a normal tissue-targeted, T2-reducing contrast agent offers a promising approach to imaging PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Self-citation
Cited by
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852
Mahmoudi, M., Sant, S., Wang, B., Laurent, S., & Sen, T. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.05.006 · Cited by 1,881
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
Veiseh, O., Gunn, J. W., & Zhang, M. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.002 · Cited by 1,832
Introduction to metallic nanoparticles
Mody, V., Siwale, R., Singh, A., & Mody, H. (2010) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.72127 · Cited by 1,025
Multifunctional magnetic nanoparticles for targeted imaging and therapy
MCCARTHY, J., & WEISSLEDER, R. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.014 · Cited by 892
Self-citationTassa, C., Shaw, S. Y., & Weissleder, R. (2011) · Accounts of Chemical Research · doi:10.1021/ar200084x · Cited by 653
Self-citationApplications of nanoparticles in biomedical imaging
Han, X., Xu, K., Taratula, O., & Farsad, K. (2019) · Nanoscale · doi:10.1039/c8nr07769j · Cited by 637
Nanoplatforms for Targeted Molecular Imaging in Living Subjects
Cai, W., & Chen, X. (2007) · Small · doi:10.1002/smll.200700351 · Cited by 563
Nanoparticles for biomedical imaging
Nune, S. K., Gunda, P., Thallapally, P. K., Lin, Y.-Y., Laird Forrest, M., & Berkland, C. J. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903229031 · Cited by 450
Imaging Pancreatic Cancer Using Bioconjugated InP Quantum Dots
Yong, K.-T., Ding, H., Roy, I., Law, W.-C., Bergey, E. J., Maitra, A., & Prasad, P. N. (2009) · ACS Nano · doi:10.1021/nn8008933 · Cited by 370
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs
Wong, X. Y., Sena-Torralba, A., Álvarez-Diduk, R., Muthoosamy, K., & Merkoçi, A. (2020) · ACS Nano · doi:10.1021/acsnano.9b08133 · Cited by 363
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Huang, J., Li, Y., Orza, A., Lu, Q., Guo, P., Wang, L., Yang, L., & Mao, H. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201504185 · Cited by 292
Yu, J., Yin, W., Zheng, X., Tian, G., Zhang, X., Bao, T., Dong, X., Wang, Z., Gu, Z., Ma, X., et al. (2015) · Theranostics · doi:10.7150/thno.11802 · Cited by 266
Targeted Delivery of Multifunctional Magnetic Nanoparticles
McCarthy, J. R., Kelly, K. A., Sun, E. Y., & Weissleder, R. (2007) · Nanomedicine · doi:10.2217/17435889.2.2.153 · Cited by 255
Self-citationBiodegradable, polymeric nanoparticle delivery systems for cancer therapy
Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2007) · Nanomedicine · doi:10.2217/17435889.2.5.669 · Cited by 249
Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer
Tummers, W. S., Willmann, J. K., Bonsing, B. A., Vahrmeijer, A. L., Gambhir, S. S., & Swijnenburg, R.-J. (2018) · Pancreas · doi:10.1097/mpa.0000000000001075 · Cited by 50
“For example, by targeting the bombesin receptor, PDACwould appear by a lack of contrast agent uptake.(64) However, specificity of those potential molecular imaging targets compared with pancreatitis is still to be determined.”
Background
Metadata
- Authors
- Montet, X., Weissleder, R., & Josephson, L.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-05-26
- Volume
- 17
- Issue
- 4
- Pages
- 905-911
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- OpenAlex
- W2090514007
- Cited by
- 152
- References
- 1
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.